Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$35K Sell
24,000
-17,500
-42% -$671K 0.53% 14
2019
Q2
$161K Buy
41,500
+24,000
+137% +$1M 2.99% 8
2019
Q1
$25K Hold
17,500
– – 0.35% 11
2018
Q4
$49K Sell
17,500
-72,500
-81% -$3.17M 0.18% 41
2018
Q3
$531K Buy
+90,000
New +$3.65M 0.84% 19

Other funds holding PFE

TLP Group's PFE Position: Q3 2019 in Review

TLP Group increased its Pfizer (PFE) stake by 403% in Q3 2019, buying an estimated $350K and bringing the position to 11,400 shares worth $410K. The position accounts for 6.2% of the portfolio, ranked #5.

TLP Group first reported a position in PFE in Q4 2015 and has held it in 10 quarters since. The position peaked at $3.8M in Q4 2017. 2,322 funds tracked by Wall St. Rank hold PFE as of Q3 2019.

  • TLP Group held 11,400 shares of Pfizer worth $410K as of Q3 2019.
  • TLP Group bought 9,135 Pfizer shares in Q3 2019, an estimated $350K.
  • Pfizer made up 6.2% of TLP Group's portfolio in Q3 2019, its #5 holding.
  • TLP Group first reported a position in Pfizer in Q4 2015 and has held it in 10 quarters since.
  • TLP Group's Pfizer position peaked at $3.8M in Q4 2017.
  • 2,322 funds tracked by Wall St. Rank held Pfizer as of Q3 2019.

Based on TLP Group's 13F filing for Q3 2019, filed 11 Oct 2019.